Andrew’s research focuses on the investigation of antimicrobial resistance, antimicrobial efficacy, and dose optimisation using a combined microbiological and pharmacometrics approach.
To optimise antimicrobial drug (AMD) use, a comprehensive understanding of the pharmacodynamic (bacteriostatic/bactericidal) effect for each bacteria-drug combination is required. This can be evaluated in vitro through the determination of the minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC), and mutant prevention concentration (MPC) and using static and dynamic growth/kill assays. Resistance can be determined through molecular screening and minimal selective concentrations (MSC) explored. Pharmacokinetics is evaluated in vivo (or from literature) and emulated using the hollow-fibre infection model. Advanced PK/PD modelling allows for complex understanding of dosing and prediction of target attainment.